C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

Palao, Nerea; Sequera, Celia; Cuesta, Ángel M.; Baquero, Cristina; Bragado, Paloma; Gutiérrez-Uzquiza, Álvaro; Sánchez, Aránzazu; Guerrero, Carmen; Porrás, Almudena

doi:10.7150/ijbs.73192

Cited by 5 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C3G also regulates HPC biology [235]. C3G down-regulation favors a partial EMT associated with stemness and enhanced migration.…”

Section: C3g a New Signaling Player In Hccmentioning

confidence: 99%

New and Old Key Players in Liver Cancer

Cuesta,

Palao,

Bragado

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Liver cancer represents a major health problem worldwide with growing incidence and high mortality, hepatocellular carcinoma (HCC) being the most frequent. Hepatocytes are likely the cellular origin of most HCCs through the accumulation of genetic alterations, although hepatic progenitor cells (HPCs) might also be candidates in specific cases, as discussed here. HCC usually develops in a context of chronic inflammation, fibrosis, and cirrhosis, although the role of fibrosis is controversial. The interplay between hepatocytes, immune cells and hepatic stellate cells is a key issue. This review summarizes critical aspects of the liver tumor microenvironment paying special attention to platelets as new key players, which exert both pro- and anti-tumor effects, determined by specific contexts and a tight regulation of platelet signaling. Additionally, the relevance of specific signaling pathways, mainly HGF/MET, EGFR and TGF-β is discussed. HGF and TGF-β are produced by different liver cells and platelets and regulate not only tumor cell fate but also HPCs, inflammation and fibrosis, these being key players in these processes. The role of C3G/RAPGEF1, required for the proper function of HGF/MET signaling in HCC and HPCs, is highlighted, due to its ability to promote HCC growth and, regulate HPC fate and platelet-mediated actions on liver cancer.

show abstract

“…C3G also regulates HPC biology [235]. C3G down-regulation favors a partial EMT associated with stemness and enhanced migration.…”

Section: C3g a New Signaling Player In Hccmentioning

confidence: 99%

New and Old Key Players in Liver Cancer

Cuesta,

Palao,

Bragado

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cells were lysed and western blot protocol was carried out as previously described (42). The primary antibodies used were β-Actin (sc-47778, SCB), PRMT7 (#14762S, CST), mono-methyl arginine (#8015S, CST), PRMT5 (sc-376937, SCB), ITGα1 (sc-271034, SCB), and ITGβ4 (sc-9090, SCB).…”

Section: Protein Extraction and Immunoblottingmentioning

confidence: 99%

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer

Gutierrez-Uzquiza,

Rodrigo-Faus,

Vincelle-Nieto

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Owing to the inefficacy of available treatments, the survival rate of patients with metastatic prostate cancer (mPCa) is severely decreased. Therefore, it is crucial to identify new therapeutic targets to increase the survival of mPCa patients. This study aim was to identify the most relevant regulators of mPCa onset by performing two high-throughput CRISPR/Cas9 screenings. Furthermore, some of the top hits were validated using small interfering RNA (siRNA) technology, with protein arginine methyltransferase 7 (PRMT7) being the best candidate. Its inhibition, by genetic and pharmacological approaches, or its depletion, via CRISPR, significantly reduced mPCa cell capacities in vitro. Furthermore, PRMT7 ablation reduced mPCa appearance in chicken chorioallantoic membrane and mouse xenograft assays. Molecularly, PRMT7 reprograms the expression of several adhesion molecules through methylation of several transcription factors, such as FoxK1 or NR1H2, which results in primary tumor PCa cell adhesion loss and motility gain. Moreover, PRMT7 is upregulated in advanced stages of Spanish PCa tumor samples and PRMT7 pharmacological inhibition reduces the dissemination of mPCa cells. Thus, here is shown that PRMT7 is a potential therapeutic target and biomarker of mPCa.

show abstract

“…Cells were lysed and western blot protocol was carried out as previously described (53). The primary antibodies used were β-Actin (sc-47778, Santa Cruz Biotechnology), PRMT7 (#14762S, CST), mono-methyl arginine (Me-R4-100, CST) (#8015S, CST), PRMT5 (sc-376937, Santa Cruz Biotechnology), ITGα1 (sc-271034, Santa Cruz Biotechnology), and ITGβ4 (sc-9090, Santa Cruz Biotechnology).…”

Section: Protein Extraction and Immunoblottingmentioning

confidence: 99%

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer

Rodrigo-Faus,

Vincelle-Nieto,

Vidal

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Owing to the inefficacy of available treatments, the survival rate of patients with metastatic prostate cancer (mPCa) is severely decreased. Therefore, it is crucial to identify new therapeutic targets to increase the survival of mPCa patients. This study aim was to identify the most relevant regulators of mPCa onset by performing two high-throughput CRISPR/Cas9 screenings. Furthermore, some of the top hits were validated using small interfering RNA (siRNA) technology, with protein arginine methyltransferase 7 (PRMT7) being the best candidate. Its inhibition or depletion via CRISPR significantly reduced mPCa cell capacities in vitro. Furthermore, PRMT7 ablation reduced mPCa appearance in chicken chorioallantoic membrane and mouse xenograft assays. Molecularly, PRMT7 reprograms the expression of several adhesion molecules through methylation of several transcription factors, such as FoxK1 or NR1H2, which results in primary tumor PCa cell adhesion loss and motility gain. Moreover, PRMT7 is upregulated in advanced stages of Spanish PCa tumor samples and PRMT7 pharmacological inhibition reduces the dissemination of mPCa cells. Thus, here is shown that PRMT7 is a potential therapeutic target and biomarker of mPCa.

show abstract

C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

Cited by 5 publications

References 40 publications

New and Old Key Players in Liver Cancer

New and Old Key Players in Liver Cancer

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer

Contact Info

Product

Resources

About